4SCAR-GD2-modified T-lymphocytes

{
  "id": "MLC-T-ONC-009544",
  "term": "4SCAR-GD2-modified T-lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "Genetically modified autologous T-lymphocytes transduced with a lentiviral vector encoding a fourth generation specific chimeric antigen receptor (4SCAR) specific for the disialoganglioside GD2 and which includes the CD3zeta chain and the signaling domains of the co-stimulatory molecules CD28, CD137, and CD27 fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration of 4SCAR-GD2 T-cells, these cells target the GD2 antigen on tumor cells to induce selective toxicity against GD2-expressing tumor cells. The tumor-associated antigen (TAA) GD2 is overexpressed on the surface of neuroblastoma cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered; this binds to the drug binding FKBP12-F36V domain and activates caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation.",
  "synonyms": [
    "4SCAR-GD2 T cells",
    "4SCAR-GD2",
    "4SCAR-GD2-modified T cells",
    "GD2-specific 4th generation chimeric antigen receptor-modified T cells",
    "4S-GD2-CAR-T cells",
    "4S-GD2-CAR T cells",
    "4S-GD2-CAR-T-cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/4scar-gd2-modified-t-lymphocytes/"
}